REGNHealth careBiotechnology
$930.67
Close on Nov 4, 2026
$98.3B
Regeneron develops medicines such as Eylea for eye disease and, with Sanofi, Dupixent for allergic conditions.
Useful context, but not the main focus.
Drag across the chart to compare two days.Touch the chart with two fingers to compare two days.
What it is · Why it matters · How to read it in context.
Annual figures, fiscal years 2021-2025.
Financial figures come from company filings with the U.S. Securities and Exchange Commission (SEC). Latest filing used: October 30, 2026. Stock prices are end-of-day closing prices.